-
Sector Analysis
Diabetic Retinopathy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Diabetic Retinopathy Therapeutics. • In 2024, there were more than 46 million ldiagnosed prevalent cases of DR in the 16 countries covered in GlobalData’s epidemiology forecast. • Currently, the DR market is saturated with generic drugs, and the platelet activating factor (PAF) inhibitor drug class dominates the approved innovator drugs currently available to treat DR. • The DR pipeline holds 140 molecules, with three assets in...
-
Product Insights
Diabetic Retinopathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Diabetic Retinopathy Clinical Trial Report Overview A total of 818 diabetic retinopathy clinical trials were conducted as of October 2024. The diabetic retinopathy clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · North America · ...
-
Product Insights
Diabetic Retinopathy - Drugs In Development, 2024
Empower your strategies with our Diabetic Retinopathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings in the vision (floaters), blurred vision, fluctuating vision, vision loss, and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. The Diabetic Retinopathy drugs in development market research report provide comprehensive information on...
-
Product Insights
Proliferative Diabetic Retinopathy (PDR) - Drugs In Development, 2024
Empower your strategies with our Proliferative Diabetic Retinopathy (PDR) – Drugs In Development, 2024 report and make more profitable business decisions. Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. PDR occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue, causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. Symptoms include spots or dark...
-
Product Insights
Non-Proliferative Diabetic Retinopathy (NPDR) - Drugs In Development, 2024
Empower your strategies with our Non-Proliferative Diabetic Retinopathy (NPDR) – Drugs In Development, 2024 report and make more profitable business decisions. Non-proliferative diabetic retinopathy (NPDR) is the early stage of the disease in which symptoms will be mild or nonexistent. In NPDR, the blood vessels in the retina are weakened. Tiny bulges in the blood vessels, called microaneurysms, may leak fluid into the retina. This leakage may lead to swelling of the macula. The Non-Proliferative Diabetic Retinopathy (NPDR) drugs in development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.